Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2018, Article ID 5689030, 5 pages
https://doi.org/10.1155/2018/5689030
Research Article

Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse

Department of Endocrine, Ningbo No. 2 Hospital, No. 41, Xibei Street, Ningbo, 315000 Zhejiang, China

Correspondence should be addressed to Jianhui Li; moc.621@gtiuhnaijil

Received 22 December 2017; Accepted 11 February 2018; Published 11 March 2018

Academic Editor: Claudio Casella

Copyright © 2018 Jianhui Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. De Leo, S. Y. Lee, and L. E. Braverman, “Hyperthyroidism,” Lancet, vol. 388, no. 10047, pp. 906–918, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. G. A. Brent, “Clinical practice. Graves’ disease,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2594–2605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Sundaresh, J. P. Brito, Z. Wang et al., “Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 9, pp. 3671–3677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. D. S. Cooper, “Antithyroid drugs,” The New England Journal of Medicine, vol. 352, no. 9, pp. 905–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. X. G. Vos, E. Endert, A. H. Zwinderman, J. G. P. Tijssen, and W. M. Wiersinga, “Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism,” The Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 4, pp. 1381–1389, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Mazza, M. Carlini, D. Flecchia et al., “Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study,” Journal of Endocrinological Investigation, vol. 31, no. 10, pp. 866–872, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Langenstein, D. Schork, K. Badenhoop, and E. Herrmann, “Relapse prediction in Graves disease: towards mathematical modeling of clinical, immune and genetic markers,” Reviews in Endocrine & Metabolic Disorders, vol. 17, no. 4, pp. 571–581, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. J. K. Kolls and A. Linden, “Interleukin-17 family members and inflammation,” Immunity, vol. 21, no. 4, pp. 467–476, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Nanba, M. Watanabe, N. Inoue, and Y. Iwatani, “Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease,” Thyroid, vol. 19, no. 5, pp. 495–501, 2009. View at Publisher · View at Google Scholar
  10. J. Li, Y. Cai, X. Sun, D. Yao, and J. Xia, “MiR-346 and TRAb as predicative factors for relapse in Graves’ disease within one year,” Hormone and Metabolic Research, vol. 49, no. 3, pp. 180–184, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Kamath, M. A. Adlan, and L. D. Premawardhana, “The role of thyrotrophin receptor antibody assays in Graves’ disease,” Journal of Thyroid Research, vol. 2012, Article ID 525936, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Orgiazzi and A. M. Madec, “Reduction of the risk of relapse after withdrawal of medical therapy for Graves’ disease,” Thyroid, vol. 12, no. 10, pp. 849–853, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Kwon, W. G. Kim, E. K. Jang et al., “Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves disease,” Endocrinology and Metabolism, vol. 31, no. 2, pp. 300–310, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Zimmermann-Belsing, B. Nygaard, A. K. Rasmussen, and U. Feldt-Rasmussen, “Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves’ disease,” European Journal of Endocrinology, vol. 146, no. 2, pp. 173–177, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Zaaber, S. Mestiri, H. Hammedi et al., “Association of interleukin-1B and interleukin-4 gene variants with autoimmune thyroid diseases in Tunisian population,” Immunological Investigations, vol. 45, no. 4, pp. 284–297, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Eshaghkhani, M. H. Sanati, M. Nakhjavani et al., “Disturbed Th1 and Th2 balance in patients with Graves’ disease,” Minerva Endocrinologica, vol. 41, no. 1, pp. 28–36, 2016. View at Google Scholar
  17. K. H. G. Mills, “Induction, function and regulation of IL-17-producing T cells,” European Journal of Immunology, vol. 38, no. 10, pp. 2636–2649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. K. Wong, L. C. W. Lit, L. S. Tam, E. K. M. Li, P. T. Y. Wong, and C. W. K. Lam, “Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity,” Clinical Immunology, vol. 127, no. 3, pp. 385–393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. K. Bedoya, B. Lam, K. Lau, and J. Larkin 3rd, “Th17 cells in immunity and autoimmunity,” Clinical and Developmental Immunology, vol. 2013, Article ID 986789, 16 pages, 2013. View at Publisher · View at Google Scholar
  20. Q. Yuan, Y. Zhao, X. Zhu, and X. Liu, “Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves’ disease model,” Journal of Endocrinological Investigation, vol. 40, no. 4, pp. 397–407, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Wei, M. Guan, Y. Qin et al., “Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves’ ophthalmopathy,” Endocrine Journal, vol. 61, no. 11, pp. 1087–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Zheng, P. Ye, and C. Liu, “The role of the IL-23/IL-17 axis in the pathogenesis of Graves’ disease,” Endocrine Journal, vol. 60, no. 5, pp. 591–597, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Komiyama, S. Nakae, T. Matsuki et al., “IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 177, no. 1, pp. 566–573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Lubberts, L. A. B. Joosten, B. Oppers et al., “IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis,” Journal of Immunology, vol. 167, no. 2, pp. 1004–1013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Xu and X. Cao, “Interleukin-17 and its expanding biological functions,” Cellular & Molecular Immunology, vol. 7, no. 3, pp. 164–174, 2010. View at Publisher · View at Google Scholar · View at Scopus